166 related articles for article (PubMed ID: 12639293)
101. A Highly Bioactive Lys-Deficient IFN Leads to a Site-Specific Di-PEGylated IFN with Equivalent Bioactivity to That of Unmodified IFN-α2b.
Imada T; Moriya K; Uchiyama M; Inukai N; Hitotsuyanagi M; Masuda A; Suzuki T; Ayukawa S; Tagawa YI; Dohmae N; Kohara M; Yamamura M; Kiga D
ACS Synth Biol; 2018 Nov; 7(11):2537-2546. PubMed ID: 30277749
[TBL] [Abstract][Full Text] [Related]
102. Targeting multiple angiogenic pathways for the treatment of neuroblastoma.
Williams RF; Myers AL; Sims TL; Ng CY; Nathwani AC; Davidoff AM
J Pediatr Surg; 2010 Jun; 45(6):1103-9. PubMed ID: 20620303
[TBL] [Abstract][Full Text] [Related]
103. Effect of thalidomide in different tumors in rodents.
Palencia G; Arrieta O; Ríos C; Altagracia M; Kravzov J; Sotelo J
J Exp Ther Oncol; 2002; 2(3):158-62. PubMed ID: 12415632
[TBL] [Abstract][Full Text] [Related]
104. [Treatment of multiple angiomatosis involving the skeleton and the abdominal and thoracic cavities with interferon alpha, thalidomide and zoledronate].
Adam Z; Krikavová L; Krejcí M; Mechl M; Pour L; Moulis M; Vanícek J; Neumann C; Navrátil M; Veselý K; Vorlícek J
Vnitr Lek; 2008 Jun; 54(6):653-64. PubMed ID: 18672578
[TBL] [Abstract][Full Text] [Related]
105. Antitumor effect of human recombinant interferon-beta against human melanomas transplanted into nude mice.
Gomi K; Morimoto M; Nakamizo N
J Pharmacobiodyn; 1984 Dec; 7(12):951-61. PubMed ID: 6533284
[TBL] [Abstract][Full Text] [Related]
106. Differential effects of thalidomide on angiogenesis and tumor growth in mice.
Belo AV; Ferreira MA; Bosco AA; Machado RD; Andrade SP
Inflammation; 2001 Apr; 25(2):91-6. PubMed ID: 11321364
[TBL] [Abstract][Full Text] [Related]
107. Synergistic interactions between interferon beta and carboplatin on SK-MEL 28 human melanoma cell growth inhibition in vitro.
Hübner B; Eckert K; Garbe C; Maurer HR
J Cancer Res Clin Oncol; 1995; 121(2):84-8. PubMed ID: 7883780
[TBL] [Abstract][Full Text] [Related]
108. Regulation of neoplastic angiogenesis.
Fidler IJ
J Natl Cancer Inst Monogr; 2001; (28):10-4. PubMed ID: 11158201
[TBL] [Abstract][Full Text] [Related]
109. Antiproliferative activity of various flavonoids and related compounds: additive effect of interferon-alpha2b.
Blank VC; Poli C; Marder M; Roguin LP
Bioorg Med Chem Lett; 2004 Jan; 14(1):133-6. PubMed ID: 14684314
[TBL] [Abstract][Full Text] [Related]
110. Interferon in combination with antitumourigenic phenyl derivatives: potentiation of IFN alpha activity in-vitro.
Samid D; Yeh TJ; Shack S
Br J Haematol; 1991 Oct; 79 Suppl 1():81-3. PubMed ID: 1931716
[TBL] [Abstract][Full Text] [Related]
111. Enhanced antitumor efficacy of a vascular disrupting agent combined with an antiangiogenic in a rat liver tumor model evaluated by multiparametric MRI.
Chen F; Feng Y; Zheng K; De Keyzer F; Li J; Feng Y; Cona MM; Wang H; Jiang Y; Yu J; Marchal G; Verfaillie C; De Geest B; Oyen R; Ni Y
PLoS One; 2012; 7(7):e41140. PubMed ID: 22815943
[TBL] [Abstract][Full Text] [Related]
112. In vivo system to detect long-term continuous release of bioactive interleukin-2 by immunopharmacological depot preparations in nude mice with human tumors.
Huland E; Falk B; Hübner D; Huland H
J Cancer Res Clin Oncol; 1995; 121(5):285-90. PubMed ID: 7768966
[TBL] [Abstract][Full Text] [Related]
113. Enhancement of tumor growth by basement membrane: modulation of growth and angiogenesis by laminin-derived synthetic peptides.
Kibbey MC; Yamamura K; Jun SH; Grant DS; Kleinman HK
Cancer Treat Res; 1994; 71():267-75. PubMed ID: 7524594
[No Abstract] [Full Text] [Related]
114. Anticancer and some biological activities of thiazinotrienomycin B.
Hosokawa N; Iinuma H; Takeuchi T; Sato S; Yamori T; Tsuchiya KS; Hori M
J Antibiot (Tokyo); 2000 Mar; 53(3):306-8. PubMed ID: 10819304
[No Abstract] [Full Text] [Related]
115. Interferons as antiangiogenic agents.
Lindner DJ
Curr Oncol Rep; 2002 Nov; 4(6):510-4. PubMed ID: 12354364
[TBL] [Abstract][Full Text] [Related]
116. Cortisone inhibition of tumor angiogenesis measured by a quantitative colorimetric assay in mice.
Lee KE; Iwamura M; Cockett AT
Cancer Chemother Pharmacol; 1990; 26(6):461-3. PubMed ID: 1699679
[TBL] [Abstract][Full Text] [Related]
117. Development of a murine animal model of depression for repeated dosing with human interferon alpha.
Siddegowda NK; Kumar Rao NS; Andrade C
Indian J Psychiatry; 2011 Jul; 53(3):239-43. PubMed ID: 22135443
[TBL] [Abstract][Full Text] [Related]
118. The Snark is a Boojum: the continuing problem of drug resistance in the antiangiogenic era.
Miller KD; Sweeney CJ; Sledge GW
Ann Oncol; 2003 Jan; 14(1):20-8. PubMed ID: 12488288
[TBL] [Abstract][Full Text] [Related]
119. Serum immunoglobulin fused interferon-alpha inhibited tumor growth in athymic mice bearing colon 26 adenocarcinoma cells.
Kim JS; Yu KN; Noh MS; Woo MA; Park SJ; Park JH; Hua J; Cho HS; Hwang SK; Lee ES; Chung YS; Choi IY; Kwon SC; Cho MH
J Vet Sci; 2008 Mar; 9(1):45-50. PubMed ID: 18296888
[TBL] [Abstract][Full Text] [Related]
120. Antiangiogenic therapy for liver metastasis of gastrointestinal malignancies.
Konno H; Tanaka T; Baba M; Kanai T; Nakamura S
J Hepatobiliary Pancreat Surg; 1999; 6(1):1-6. PubMed ID: 10436231
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
